NAGLU — Alpha-N-Acetylglucosaminidase

NAGLU — Alpha-N-Acetylglucosaminidase

Introduction

[NAGLU](/proteins/naglu-protein) (Alpha-N-Acetylglucosaminidase) is a lysosomal enzyme essential for the degradation of [heparan sulfate](/entities/heparan-sulfate) glycosaminoglycans. Mutations in NAGLU cause [mucopolysaccharidosis type IIIB (MPS IIIB)](/diseases/mucopolysaccharidosis-iii), also known as [Sanfilippo syndrome type B](/diseases/sanfilippo-syndrome), a devastating neurodegenerative lysosomal storage disorder. This page provides detailed information about NAGLU's structure, function, and role in disease processes. [@yogalingam2002]

NAGLU — Alpha-N-Acetylglucosaminidase

Introduction

[NAGLU](/proteins/naglu-protein) (Alpha-N-Acetylglucosaminidase) is a lysosomal enzyme essential for the degradation of [heparan sulfate](/entities/heparan-sulfate) glycosaminoglycans. Mutations in NAGLU cause [mucopolysaccharidosis type IIIB (MPS IIIB)](/diseases/mucopolysaccharidosis-iii), also known as [Sanfilippo syndrome type B](/diseases/sanfilippo-syndrome), a devastating neurodegenerative lysosomal storage disorder. This page provides detailed information about NAGLU's structure, function, and role in disease processes. [@yogalingam2002]

<div class="infobox infobox-gene"> [@neufeld2014]
<div class="infobox-header">NAGLU Gene</div> [@aaron1997]
<div class="infobox-row"> [@valstar2008]
<div class="infobox-label">Gene Symbol</div> [@heldermon2007]
<div class="infobox-value">NAGLU</div> [@shapiro2017]
</div> [@sardiello2009]
<div class="infobox-row"> [@cressant2007]
<div class="infobox-label">Full Name</div> [@langfordsmith2014]
<div class="infobox-value">Alpha-N-acetylglucosaminidase</div> [@tardieu2014]
</div> [@matsumoto2023]
<div class="infobox-row">
<div class="infobox-label">Chromosomal Location</div>
<div class="infobox-value">17q21.2</div>
</div>
<div class="infobox-row">
<div class="infobox-label">NCBI Gene ID</div>
<div class="infobox-value"><a href="https://www.ncbi.nlm.nih.gov/gene/4668" target="_blank">4668</a></div>
</div>
<div name="omim-link">
<div class="infobox-label">OMIM</div>
<div class="infobox-value"><a href="https://www.omim.org/entry/609701" target="_blank">609701</a></div>
</div>
<div class="infobox-row">
<div class="infobox-label">Ensembl ID</div>
<div class="infobox-value">ENSG00000108784</div>
</div>
<div class="infobox-row">
<div class="infobox-label">UniProt ID</div>
<div class="infobox-value"><a href="https://www.uniprot.org/uniprot/P54802" target="_blank">P54802</a></div>
</div>
<div class="infobox-row">
<div class="infobox-label">Associated Diseases</div>
<div class="infobox-value">[Mucopolysaccharidosis IIIB](/diseases/mucopolysaccharidosis-iii), [Sanfilippo Syndrome Type B](/diseases/sanfilippo-syndrome)</div>
</div>
<div class="infobox-row">
<div class="infobox-label">Inheritance</div>
<div class="infobox-value">Autosomal Recessive</div>
</div>
<div class="infobox-row">
<div class="infobox-label">Protein Class</div>
<div class="infobox-value">Lysosomal enzyme, Glycosylhydrolase</div>
</div>
</div>

Overview

[NAGLU](/proteins/naglu-protein) encodes alpha-N-acetylglucosaminidase, a lysosomal enzyme that catalyzes the N-acetylglucosaminide hydrolysis in heparan sulfate glycosaminoglycans. It is the third enzyme in the stepwise degradation of [heparan sulfate](/entities/heparan-sulfate), working in concert with [N-sulfoglucosamine sulfohydrolase (SGSH)](/proteins/sgssh-protein) and [heparan N-sulfatase (HGSNAT)](/proteins/hgsnat-protein) to completely break down HS chains [1].

Mutations in NAGLU cause [mucopolysaccharidosis type IIIB (MPS IIIB)](/diseases/mucopolysaccharidosis-iii), also known as [Sanfilippo syndrome type B](/diseases/sanfilippo-syndrome), a neurodegenerative lysosomal storage disorder. The enzyme deficiency leads to accumulation of [heparan sulfate](/entities/heparan-sulfate) in lysosomes throughout the body, particularly affecting the brain and causing progressive neurodegeneration [2].

Function

NAGLU encodes alpha-N-acetylglucosaminidase, a lysosomal enzyme that catalyzes the N-acetylglucosaminide hydrolysis in [heparan sulfate](/entities/heparan-sulfate) glycosaminoglycans. This enzyme is essential for the stepwise degradation of heparan sulfate (HS), a component of the extracellular matrix and cell surface.

Catalytic Mechanism

NAGLU belongs to the family of [glycosylhydrolases](/mechanisms/glycosylation-neurodegeneration) and specifically cleaves the α-N-acetylglucosaminide linkage in HS substrates. The enzyme requires an acidic pH optimum (pH 4.5-5.0) for optimal activity, consistent with the lysosomal environment [3].

Key functions include:

• Lysosomal catabolism: Breaks down heparan sulfate in the lysosome
• [Autophagy](/mechanisms/autophagy-lysosomal-pathway) regulation: HS accumulation impairs [autophagic flux](/mechanisms/autophagy-lysosomal-pathway)
• Neuronal health: Essential for normal neuronal function and survival
• Cellular homeostasis: Prevents toxic accumulation of GAGs

Protein Structure

The NAGLU protein is a homodimer with each subunit approximately 74 kDa. The enzyme contains a signal peptide directing it to the lysosome and a catalytic domain responsible for substrate hydrolysis [3].

Disease Associations

Mucopolysaccharidosis type IIIB (MPS IIIB), also known as Sanfilippo syndrome type B, is caused by autosomal recessive mutations in NAGLU. It is one of four subtypes of Sanfilippo syndrome (MPS IIIA-D), each caused by deficiency of a different enzyme in HS degradation [2][4].

Genotype-Phenotype Correlation

| Mutation Type | Effect | Severity |
|--------------|--------|----------|
| Null mutations | No enzyme activity | Severe, early onset |
| Missense mutations | Reduced activity | Variable severity |
| Late-onset variants | Partial activity | Attenuated phenotype |

Common pathogenic variants:

• p.Arg626Trp — most common missense variant
• p.Glu401Lys — severe variant
• p.Trp398\* — truncating variant
• p.Ile490Serfs\*9 — frameshift variant

Pathogenesis

Neurodegeneration in MPS IIIB involves multiple interconnected mechanisms [5][6]:

Clinical Features

• Progressive cognitive decline
• Behavioral problems (hyperactivity, aggression, sleep disturbances)
• Motor impairment and ataxia
• Speech and language delays
• Seizures (in later stages)
• Coarse facial features (mild)
• Hearing loss

Expression and Regulation

NAGLU is expressed ubiquitously with highest levels in:

• Liver and spleen (highest expression)
• Brain ([neurons](/cell-types/neurons) and [astrocytes](/cell-types/astrocytes))
• Fibroblasts

Protein Interactions

NAGLU interacts with several proteins in its role in lysosomal heparan sulfate catabolism:

| Partner Protein | Interaction Type | Functional Significance |
|-----------------|------------------|-------------------------|
| [SGSH](/genes/sgsh) | Sequential processing | Works upstream in HS degradation |
| [HGSNAT](/proteins/hgsnat-protein) | Sequential processing | Works upstream in HS degradation |
| [GNS](/proteins/gns-protein) | Sequential processing | Works downstream in HS degradation |
| [GAGNS](/proteins/gagns-protein) | Sequential processing | Works downstream in HS degradation |
| [LAMP1](/proteins/lamp1) | Lysosomal targeting | Mediates lysosomal localization |
| [LAMP2](/proteins/lamp2) | Lysosomal targeting | Mediates lysosomal localization |
| [TFEB](/proteins/tfeb) | Transcriptional regulation | Activates expression under starvation |

Animal Models

Several animal models have been developed to study MPS IIIB [8][9]:

Murine Models

• Naglu^-/- mice: Recapitulate key features of human disease including accumulation of HS, neuroinflammation, and behavioral deficits
• AAV-mediated gene therapy: Shows promise in crossing the [blood-brain barrier](/mechanisms/bbb-dysfunction-pathway) and delivering functional NAGLU

Phenotypic Characteristics

• Progressive accumulation of HS in brain and peripheral tissues
• Elevated lysosomal storage in [neurons](/entities/neurons) and [astrocytes](/entities/astrocytes)
• Microglial activation and neuroinflammation
• Learning and memory deficits
• Shorter lifespan compared to wild-type

Therapeutic Implications

Multiple therapeutic strategies are being developed for MPS IIIB [10][11]:

Enzyme Replacement Therapy (ERT)

• Recombinant NAGLU administration
• Challenges: [Blood-brain barrier](/mechanisms/bbb-dysfunction-pathway) limits CNS delivery

Gene Therapy

• AAV vectors (AAV9, AAVrh.10) for CNS delivery
• Intrathecal or intravenous administration
• Clinical trials ongoing

Substrate Reduction Therapy

• Reduce HS biosynthesis to decrease substrate accumulation
• Small molecule approaches in development

Chaperone Therapy

• Pharmacological chaperones to stabilize mutant enzyme
• Best for missense mutations with residual activity

Stem Cell Therapy

• Hematopoietic stem cell transplantation
• Mesenchymal stem cell approaches

Brain Atlas Resources

Expression data from the [Allen Human Brain Atlas](/allen-human-brain-atlas) shows NAGLU expression across multiple brain regions, with higher expression in [neurons](/cell-types/neurons) compared to [glial cells](/cell-types/astrocytes). Single-cell data indicates variable expression in different [neuronal subtypes](/cell-types/cortical-pyramidal-neurons).

Background

The study of NAGLU and Sanfilippo syndrome type B has evolved significantly since the disease was first described in 1963 by Dr. Sylvester Sanfilippo. The identification of NAGLU as the causative gene in 1995 enabled molecular diagnosis and carrier testing [1].

Historical milestones:

• 1963: First description of Sanfilippo syndrome
• 1995: Identification of NAGLU as the causative gene
• 2002: Development of murine models
• 2010s: First clinical trials for gene therapy

See Also

• [Mucopolysaccharidosis III](/diseases/mucopolysaccharidosis-iii)
• [Sanfilippo Syndrome](/diseases/sanfilippo-syndrome)
• [Lysosomal Storage Disorders](/diseases/lysosomal-storage-disorders)
• [Heparan Sulfate](/entities/heparan-sulfate)
• [Autophagy-Lysosomal Pathway](/mechanisms/autophagy-lysosomal-pathway)
• [Neuroinflammation](/mechanisms/neuroinflammation)
• [SGSH Gene](/sgsh-gene)
• [HGSNAT Gene](/proteins/hgsnat-protein)
• [GNS Gene](/proteins/gns-protein)

External Links

• <a href="https://www.ncbi.nlm.nih.gov/gene/4668" target="_blank">NCBI Gene: NAGLU</a>
• <a href="https://www.uniprot.org/uniprot/P54802" target="_blank">UniProt: NAGLU (P54802)</a>
• <a href="https://www.omim.org/entry/609701" target="_blank">OMIM: 609701</a>
• <a href="https://www.ncbi.nlm.nih.gov/books/NBK546642/" target="_blank">GeneReviews: NAGLU-Related MPS</a>
• <a href="https://clinicaltrials.gov/search?cond=MPS+IIIB" target="_blank">Clinical Trials: MPS IIIB</a>

Brain Atlas Resources

• Allen Human Brain Atlas: [NAGLU — Alpha-N-Acetylglucosaminidase expression search](https://human.brain-map.org/microarray/search/show?search_term=NAGLU)
• Allen Cell Type Atlas: [Transcriptomic cell type reference](https://portal.brain-map.org/atlases-and-data/rnaseq)
• Allen Mouse Brain Atlas: [NAGLU — Alpha-N-Acetylglucosaminidase search](https://mouse.brain-map.org/search/index.html?query=NAGLU)

References

Pathway Diagram

The following diagram shows the key molecular relationships involving NAGLU — Alpha-N-Acetylglucosaminidase discovered through SciDEX knowledge graph analysis: